Hua Hin Forum

It's for parasite infections. Who would have thought.

https://en.wikipedia.org/wiki/Ivermectin

Edit: This wiki entry mentions it's use against Covid and this particular doctor who is recommending it. It's down towards the bottom of the article.

What's interesting is it was discovered from a soil sample in Japan in the 1970's and has never been found anywhere else in the world since.

There is NO evidence that this drug works against Covid. Masses of info all over the net.

Get Trump to endorse it. That should slim republican numbers and leave the more sensible people to lead effectively.

Each province's daily domestic COVID-19 cases update in Thailand on Friday  4th June
FB link for reference: https://www.facebook.com/nbtworld

Why You Should Not Use Ivermectin to Treat or Prevent COVID-19

https://www.fda.gov/consumers/consumer- ... t-covid-19

HHTel wrote: ↑Fri Jun 04, 2021 2:15 pm There is NO evidence that this drug works against Covid. Masses of info all over the net.

Get Trump to endorse it. That should slim republican numbers and leave the more sensible people to lead effectively.

https://c19early.com

Now, the question is why would any cheap drug, where the patent has expired, that shows high effectiveness have a campaign against it to discredit it?

Today's Brief:

He's struggling isn't he. Firstly, his numbers were all over the place and didn't add up. Later he got June and July confused several times.
I don't envy his job.

So vaccines are being rationed on a weekly basis dependent upon the number of cases in each province. High infection rates, more vaccines. Low cases, not so many. That doesn't put PKK in the firing line for vaccines and what about the 'white' provinces? Do they get none because they have no cases?

What a mess.

Now, the question is why would any cheap drug, where the patent has expired, that shows high effectiveness have a campaign against it to discredit it?

A controversy subsequently blew up over an article by the Front Line COVID-19 Critical Care Alliance, a group of doctors and researchers that lobbies for the use of ivermectin.

This article, summarising multiple small studies of the effects of ivermectin on COVID-19 patients, was provisionally accepted for publication in the journal Frontiers in Pharmacology in January 2021 but then rejected and removed from the journal’s website in March. The journal’s editor stated that the standard of evidence in the paper was insufficient and that the authors were inappropriately promoting their own ivermectin-based treatment.

One larger randomised clinical trial was published in March 2021. This showed no effect of ivermectin on duration of symptoms of adults with mild COVID-19.

It's being called the 'new hydroxychloroquine' and we know what happened there.

It's mainly a treatment for parasites on animals with minimal treatment for 'roundworm' in humans.

In the so-called studies, none of them referred to the treatment Invermectin in isolation but were carried out with a cocktail of various other drugs.

HHTel wrote: ↑Fri Jun 04, 2021 3:16 pm So vaccines are being rationed on a weekly basis dependent upon the number of cases in each province. High infection rates, more vaccines. Low cases, not so many. That doesn't put PKK in the firing line for vaccines and what about the 'white' provinces? Do they get none because they have no cases?

What about Recharge?

As always, the question to ask is: who paid for the trials/studies? If the answer is the manufacturer then, you know what the outcome will be. Unless the trials are done by an independent lab, they are invalid.

It'll be slow recharge rather than fast recharge.

Another pineapple factory outbreak might help.

Sent from my Redmi Note 8 Pro using Tapatalk

31 Covid fatalities, 2,631 new cases

https://www.bangkokpost.com/thailand/ge ... -new-cases

There were 31 new Covid-19 fatalities and 2,631 new cases confirmed on Thursday, the Public Health Ministry reported on Friday morning.

There were 2,442 new infections dected in the general populace and 189 in prison inmates.

Over the previous 24 hours, 2,493 Covid-19 patients recovered and were discharged from hospitals.

Since April 1, around when the third wave of Covid-19 began, there have been 143,116 Covid-19 patients, 93,271 of whom have recovered.

Since the pandemic started early last year, there have been 171,979 Covid-19 cases.

The death toll was at 1,083 in the third wave of Covid-19 starting in April and 1,177 from the beginning of the pandemic early last year.

Apisamai Srirangson, spokeswoman for the Centre for Covid-19 Situation Administration, said in the afternoon briefing that the 31 new fatalities were aged 17-97 years. Sixteen were male and 15 female. There were 20 deaths in Bangkok, four in Samut Prakan, two in Chiang Mai and one each in Kamphaeng Phet, Chanthaburi, Nakhon Pathom, Roi Et and Uthai Thani.

Nineteen of the fatalities had hypertension. Ten caught Covid-19 from family members and seven visited outbreak areas.

The 2,631 new cases over the past 24 hours included 2,391 local infections and 51 imported cases. Of the local infections, 1,306 were confirmed at hospitals and 1,085 via mass testing.

Bangkok logged the most cases, 824, followed by 460 in Pathum Thani, 202 in Samut Prakan, 198 in Phetchaburi, 153 in Nonthaburi, 101 in Chon Buri, 73 in Samut Sakhon, 41 in Songkhla, 36 in Nakhon Pathom and 34 in Trang.

Dr Apisamai said Bangkok had 52 Covid-19 clusters in 32 districts including two new ones – a construction workers’ camp in Chatuchak district and Hua Pa community in Suan Luang district.

Pathum Thani had many Covid-19 cases at a chicken processing plant in Lam Luk Ka district, where 854 of the 2,073 workers tested positive for Covid-19. At the province's Simummuang market, also in Lam Luk Ka, 1,569 of 22,412 workers tested positive.

In Samut Prakan, there were Covid-19 clusters at a bleaching factory where 27 of 415 workers tested positive and an export-oriented furniture factory where five of 186 were confirmed with the disease, she said.

"The Department of Disease Control was concerned about factories where workers’ living quarters were packed and they usually gathered and shared places and cups like what happened at construction workers’ camps. The disease was found on coolers and workers partied after work. They shared cigarettes,” Dr Apisamai said.

The 51 imported cases were arrivals from Ivory Coast (1), Equatorial Guinea (1), Sudan (1), Egypt (2), the United Arab Emirates (2), Cambodia (37 Thais including 11 illegal returnees who were gamblers and online administrators), Malaysia (6) and Myanmar (1 illegal Thai woman arrested in Mae Sot district of Tak).

Dr Apisamai urged local officials and people near the border to watch out for illegal returnees, saying they could carry Covid-19 mutant variants and jeopardise people in the country.

As of Thursday, 50,105 patients were at hospitals, including 1,182 critically ill and 376 dependent on ventilators.

Global Covid-19 cases rose by 471,294 in 24 hours to 172.89 million. The worldwide death toll went up by 10,296 to 3.72 million. US had the most cases at 34.17 million, up 17,821, and the most deaths at 611,611, up 574. India was second with 28.57 million cases, up 131,371, and 340,719 deaths, up 2,706.

HHTel wrote: ↑Fri Jun 04, 2021 3:50 pm

Now, the question is why would any cheap drug, where the patent has expired, that shows high effectiveness have a campaign against it to discredit it?

A controversy subsequently blew up over an article by the Front Line COVID-19 Critical Care Alliance, a group of doctors and researchers that lobbies for the use of ivermectin.

This article, summarising multiple small studies of the effects of ivermectin on COVID-19 patients, was provisionally accepted for publication in the journal Frontiers in Pharmacology in January 2021 but then rejected and removed from the journal’s website in March. The journal’s editor stated that the standard of evidence in the paper was insufficient and that the authors were inappropriately promoting their own ivermectin-based treatment.

One larger randomised clinical trial was published in March 2021. This showed no effect of ivermectin on duration of symptoms of adults with mild COVID-19.

It's being called the 'new hydroxychloroquine' and we know what happened there.

It's mainly a treatment for parasites on animals with minimal treatment for 'roundworm' in humans.

In the so-called studies, none of them referred to the treatment Invermectin in isolation but were carried out with a cocktail of various other drugs.

In March this year, New York Times broke a story, repeated around the world, reporting a trial that proved “Ivermectin had no effect”. The Lopez-Medina trial, published in JAMA, a leading medical journal, was held as the gold standard for Ivermectin RCT’s. In the trial, reminiscent of a “big tobacco” hit-job, vaccine manufactures paid the researchers (documented in the papers Conflicts Of Interests section). There are many faults in the trial. Among them, they accidentally gave Ivermectin to both arms of the trial and changed the trials primary outcome, mid-trial, three times. Normally, nobody would pay a trial any attention after these significant problems. As the trial was on a young heathy population, in an area with high Ivermectin use, freely available from the mayor during their first COVID wave, you were allowed on the trial if you hadn’t taken Ivermectin for 5 days, despite it’s effects being noticeable up to a month after a single dose. Surprisingly less than 3% of the participants had disease progression, against an expectation of 18%. The rare but specific Ivermectin side effect, blurred vision, was within 0,3% (11.3/11.6%) of both groups as were other side effects. The results were collected telephonically and no physical examination was done. From their result, with surprisingly few people having disease progression (some suggest that the trial inadvertently proves Ivermectin’s efficiency), it’s not possible to arrive at the conclusion that Ivermectin doesn’t work, which is what they did, and the media bought it.

Now, one of the treatment drugs in Thailand is Favipiravir. How effective is that?

Conclusion
Overall, Favipiravir possibly exerted no significant beneficial effect in the term of mortality in the general group of patients with mild to moderate COVID-19. We should consider that perhaps the use of antivirals once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting.
https://www.nature.com/articles/s41598-021-90551-6